Samsung unveils
Simband – a new digital health platform to track your health better
Samsung on Wednesday
unveiled a new digital health technology platform that uses sensors to track a
range of body functions such as heart rate and blood pressure. Unveiled at
an event in San Francisco the new platform dubbed ‘Simband’ does not include
any commercial products, but Samsung demonstrated how it might work with a
wristband.
The South Korean
electronics giant showed how a device can track measurements such as heart
rate, respiratory rate and blood pressure and collect data from a variety of
sources to help consumers better understand what is happening with
their health.
Simband will work in
tandem with a cloud-based open software platform called SAMI which securely
stores data and can provide better insights into health issues.
‘The combination of
Simband-designed sensor technologies and algorithms and SAMI-based software
will take individual understanding of the body to a new level,’ the company
said in a statement. The new tech platform in cooperation with university
researchers is part of an effort by Samsung to use digital products
to help improve health care.
‘Our bodies have
always had something to say but now, with advanced sensors, algorithms and
software, we will finally be able to tune into what the body is telling us,’
said Michael Blum of the University of California at San Francisco,
in the Samsung statement.
‘Validation of these
technologies will improve the quality of data collected and help advance the
ability to bring new products to market quickly.’
The Samsung Digital
Health Initiative is based on open hardware and software platforms and allows
the use of sensors, algorithms, and data collection and analysis that can help
consumers and health care providers.
The initiative
‘provides an exciting opportunity for the brightest minds in the technology
world to come together to develop the products that will, for the first time,
put individuals in the driver’s seat in understanding their own health and
wellness,’ said Young Sohn, president and chief strategy officer, Device
Solutions at Samsung Electronics.
‘At a time when health
care spending is at record levels and when the number of people over the age of
60 worldwide is expected to exceed more than 1.2 billion by 2025, digital
health is an incredibly important area for innovation. We believe this
initiative will be an essential first step and we invite developers and
partners across the globe to join us in creating the technologies of the future
that will help make people’s lives healthier.’
The move follows an
announcement by Google last year that it was launching a new company that could
draw on the work from technology and other sectors to combat health
problems.
Source: www.thehealthsite.com
30.05.2014
High BP medicines may increase
vision loss risk
Certain
blood pressure lowering medications may have dangerous side effects as
researchers have found a link between taking vasodilators and developing
early-stage age-related macular degeneration (AMD) that could lead to vision
loss and blindness. AMD – the deterioration of the eye’s macula, which is
responsible for the ability to see fine details clearly – affects millions
worldwide.
‘As
significant as these results may be, it is important that they be replicated
first, and if possible tested in a clinical trials setting before changing
anyone’s medication regimens,’ cautioned Ronald Klein from University of
Wisconsin’s school of medicine and public health. To reach this conclusion, the
researchers conducted a long-term population-based cohort study from 1988 to
2013 of nearly 5,000 people aged 43 to 86 years. After adjusting for age, sex
and other factors, the researchers found that using any vasodilator such as
Apresoline and Loniten, which open (dilate) the blood vessels – was associated
with a 72 percent greater risk of developing early-stage AMD. Among people who
were not taking vasodilators, an estimated 8.2 percent developed signs of early
AMD. In comparison, among those taking a vasodilator medication, 19.1 percent
developed the disease.
While the study provides risk
estimates of associations between blood pressure lowering medications and AMD
at various stages, the researchers cautioned that their study was not able to
discern effects of the medications themselves and the conditions for which
participants were taking those medications
Source: www.thehealthsite.com
30.05.2014
Adjustment with right people is always better than
argument with wrong people